Abstract
Extreme thrombocytosis (ExT) has been associated with an increased bleeding risk in myeloproliferative neoplasm (MPN) patients and is included in the high risk category in treatment guidelines. Treatment of patients with ExT has not been studied in prospective trials. To study physicians’ approaches to ExT, we distributed a web based questionnaire with clinical case scenarios to 202 members of MPN working groups. Cases included low thrombotic risk essential thrombocythemia (ET) with either JAK2V617F or CALR mutation, polycythemia vera with ExT either with or without leukocytosis, an ET patient needing urgent orthopedic surgery, and a poorly controlled ET patient with acute cerebral venous sinus thrombosis. Responses were received from 90 physicians (45 %) and were variable in most case scenarios. Country of practice had the most significant influence on physician response. The USA and Israel physicians responded similarly in most cases and differently to the Europe physicians. Treatment of asymptomatic JAK2V617F positive ET and target platelet count on cytoreduction were significantly influenced by physician years of experience. Responses were not influenced by the volume of MPN practice or by whether MPN was considered a major interest by the physician. Our results show a lack of consensus on how to manage MPN patients with ExT. Randomized controlled trials properly designed to address these questions are needed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Falanga A, Marchetti M (2014) Thrombosis in myeloproliferative neoplasms. Semin Thromb Hemost 40:348–358
Tefferi A, Barbui T (2015) Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am J Hematol 90:162–173
Barbui T, Carobbio A, Rumi E et al (2014) In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood 124:3021–3023
Carobbio A, Thiele J, Passamonti F et al (2011) Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood 117:5857–5859
Barbui T, Finazzi G, Carobbio A et al (2012) Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis). Blood 120:5128–5133
Finazzi G, Carobbio A, Guglielmelli P et al (2014) Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia. Blood 124:2611–2612
Rumi E, Pietra D, Ferretti V et al (2014) JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 123:1544–1551
Pietra D, Rumi E, Ferretti VV et al (2016) Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia 30:431–438
Klampfl T, Gisslinger H, Harutyunyan AS et al (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369:2379–90
Rotunno G, Mannarelli C, Guglielmelli P et al (2014) Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood 123:1552–1555
Patrono C, Rocca B, De Stefano V (2013) Platelet activation and inhibition in polycythemia vera and essential thrombocythemia. Blood 121:1701–1711
Konkle BA (2011) Acquired disorders of platelet function. Hematology 2011:391–396
Finazzi G, Carobbio A, Thiele J et al (2012) Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia 26:716–719
Barbui T, Barosi G, Birgegard G et al (2011) Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European leukemiaNet. J Clin Oncol 29:761–770
Bellucci S, Janvier M, Tobelem G et al (1986) Essential thrombocythemias clinical evolutionary and biological data. Cancer 58:2440–2447
Budde U, Scharf RE, Franke P et al (1993) Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood 82:1749–1757
Fenaux P, Simon M, Caulier MT et al (1990) Clinical course of essential thrombocythemia in 147 cases. Cancer 66:549–556
Sato K (1998) Plasma von Willebrand factor abnormalities in patients with essential thrombocythemia. Keio J Med 37:54–71
Raman BK, Sawdyk M, Saeed SM (1987) Essential thrombocythemia with acquired von Willebrand’s disease. Am J Clin Pathol 88:102–106
Kaifie A, Kirschner M, Wolf D et al (2016) Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. J Hematol Oncol 9:18–29
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
This work was partially supported by a grant from Associazione Italiana per la Ricerca sul Cancro (AIRC; Milan, Italy), Special Program Molecular Clinical Oncology 5x1000 to AIRC-Gruppo Italiano Malattie Mieloproliferative (AGIMM) project #1005 (A.M.V).
Conflict of interest
The authors declare that they have no conflict of interest.
Electronic supplementary material
Below is the link to the electronic supplementary material.
ESM 1
Online Resource 1: Extreme thrombocytosis questionnaire (DOCX 21 kb)
Rights and permissions
About this article
Cite this article
Koren-Michowitz, M., Lavi, N., Ellis, M.H. et al. Management of extreme thrombocytosis in myeloproliferative neoplasms: an international physician survey. Ann Hematol 96, 87–92 (2017). https://doi.org/10.1007/s00277-016-2826-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-016-2826-4